Autoimmune diseases refer to a group of approximately 100 different diseases in which the body’s immune system, mistakenly attacks and destroys a patient’s own tissue (self). There is currently no cure for autoimmune diseases, and current treatments rely on general, non-specific suppression of immune system function, frequently resulting in unacceptable side effects including infection and cancer.
There is a large unmet need for improved treatments that can suppress immune activity (restore immune tolerance) to specific organs without causing generalized immune suppression.
Treg therapy has the potential to create organ-specific immune suppression, while avoiding the general immune suppression associated with current therapies. Unlike cell therapy ex vivo expansion of Treg cells, Parvus pMHC nanomedicines harness the patient’s own immune system to trigger in vivo expansion of antigen-specific Treg cells. These Treg cells traffic to inflamed tissues and suppress local pathogenic immune responses without impairing normal immune function and as such, hold great promise for patients suffering from autoimmune diseases and chronic inflammatory conditions.
The Parvus leadership team possesses deep experience in drug discovery, translation, development, and commercialization
If you are interested in discussing a collaboration or partnership opportunity, contact info@parvustx.com.